10 March, 2015    london , United Kingdom
The challenges of drug development in CNS is well known, the recent failures of the large phase III trials in Alzheimer's disease illustrates the problem. There is however an alternative route in CNS which can prove to be more accessible to small and medium sized companies, and that is CNS Orphan diseases. Diseases such as Huntington’s disease (HD), Amyotrophic lateral scerlosis (ALS), Progressive supranuclear palsy (PSP) or Fronto Temporal Dementia (FTD) can be initial substitutes for the likes of Alzheimer's disease or Parkinson's disease in which to test the effectiveness of a drug.

Speakers:
Susan McGoldrick
Consultant
The CNS Company

Venue

Location: MSE Meeting Rooms
Here at MSE Meetings we understand the importance of space. We utilise space everyday and whether you’re looking to teach, produce or listen we’ll give you the space to do it. Located in the heart of..
Contact 103a Oxford Street London, W1D 2HG United Kingdom london , United Kingdom
0800 043 1033

Organizer

SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street London SE1 0BS United Kingdom
+44 (0) 20 7827 6000

Related events

CNS Orphan Diseases - The Alternative Route in CNS 10 March, 2015
CNS Orphan Diseases - The Alternative Route in CNS 8 April, 2014